<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Trial id="306971"><TitleDisplay>Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis</TitleDisplay><TitleOfficial>A Phase IIa, Randomized, Double-blind, Vehicle-controlled Study, To Characterize The Mechanism Of Action Of Crisaborole Ointment 2%, By Evaluation Of Efficacy And Changes In Skin Biomarkers, In Adult Subjects With Mild To Moderate Atopic Dermatitis, With A 4 Week, Open-label Extension</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03233529</Identifier><Identifier type="Organisational Study">C3291001</Identifier></Identifiers><Indications><Indication id="1102">Atopic dermatitis</Indication></Indications><BiomarkerNames><BiomarkerName id="249" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-13</BiomarkerName><BiomarkerName id="395" role="Therapeutic effect marker" type="Genomic;Proteomic">C-C motif chemokine 18</BiomarkerName><BiomarkerName id="649" role="Therapeutic effect marker" type="Genomic;Proteomic">C-C motif chemokine 17</BiomarkerName><BiomarkerName id="650" role="Therapeutic effect marker" type="Genomic;Proteomic">C-C motif chemokine 22</BiomarkerName><BiomarkerName id="3285" role="Therapeutic effect marker" type="Genomic;Proteomic">Protein S100-A12</BiomarkerName><BiomarkerName id="5924" role="Therapeutic effect marker" type="Genomic;Proteomic">Elafin</BiomarkerName><BiomarkerName id="6476" role="Therapeutic effect marker" type="Genomic;Proteomic">Keratin, type I cytoskeletal 16</BiomarkerName><BiomarkerName id="22459" role="Therapeutic effect marker" type="Genomic;Proteomic">Exosome complex component CSL4</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>crisaborole</Name><Drug id="55424">crisaborole</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="55424">crisaborole</Drug><IndicationsPioneer/><Companies><Company><Company id="18767">Pfizer Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="55424" type="Drug"><TargetEntity id="424112" type="siDrug">Crisaborole</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="1102" type="ciIndication"><TargetEntity id="L20" type="ICD10"/><TargetEntity id="691" type="ICD9"/><TargetEntity id="10012438" type="MEDDRA"/><TargetEntity id="D003876" type="MeSH"/><TargetEntity id="-1439185598" type="omicsDisease"/><TargetEntity id="456" type="siCondition"/></SourceEntity><SourceEntity id="304" type="Action"><TargetEntity id="470" type="Mechanism">Phosphodiesterase PDE4 Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2a Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="18767">Pfizer Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="304">PDE 4 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15181">Systemic antipruritic product</Class><Class id="15183">Topical antipsoriatic product</Class><Class id="2955">Non-steroidal anti-inflammatory</Class></Class><Technologies><Technology id="611">Dermatological formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2017-07-31T00:00:00Z</DateStart><DateEnd type="actual">2018-05-04T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T15:35:21Z</DateChangeLast><DateAdded>2017-08-07T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Pfizer</Affiliation><Name>Pfizer CT.gov Call Center</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Confirmed diagnosis of active atopic dermatitis (AD) with at least 6 months history prior to Screening and that has been clinically stable for 1 month&lt;/li&gt;&lt;li&gt;Investigator's Static Global Assessment (ISGA) of 2 (mild) or 3 (moderate) at baseline&lt;/li&gt;&lt;li&gt;Body surface area (BSA) covered with AD of at least 0.5% and no &gt; 10% at baseline, calculation excluding face, scalp, axilla, genitals, groin area, palms, back of the hands, and soles&lt;/li&gt;&lt;li&gt;A total of two lesions of AD at least 3  x 3 cm in size and at least 5 cm apart, with identical Lesion ISGA score of &gt;/= 3&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Clinically infected AD or requires high potency topical corticosteroids or systemic (oral/injectable) corticosteroids to manage AD&lt;/li&gt;&lt;li&gt;History of angioedema or anaphylaxis to topical products or known sensitivity to components of crisaborole ointment 2%.&lt;/li&gt;&lt;li&gt;History of cancer (except squamous or basal cell carcinoma or carcinoma in situ of the skin)&lt;/li&gt;&lt;li&gt;Previous treatment with any topical or systemic PDE4 inhibitor unless stopped for the reason of lack of efficacy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Total Sign Score (TSS): change from baseline in TSS in target lesions treated with crisaborole ointment 2% or vehicle at day 15</Description><Timeframe>Baseline, day 15</Timeframe></Measure><Measure><Description>Atopic dermatitis skin biomarker: S100A12: change from baseline in S100A12 expression in lesions treated with crisaborole ointment 2% or vehicle at Day 15</Description><Timeframe>Baseline, day 15</Timeframe></Measure><Measure><Description>Atopic dermatitis skin biomarker: CCL17: change from baseline in CCL17 expression in lesions treated with crisaborole ointment 2% or vehicle at day 15</Description><Timeframe>Baseline, day 15</Timeframe></Measure><Measure><Description>Atopic dermatitis skin biomarker: CCL18: change from baseline in CCL18 expression in lesions treated with crisaborole ointment 2% or vehicle at day 15</Description><Timeframe>Baseline, day 15</Timeframe></Measure><Measure><Description>Atopic dermatitis skin biomarker: CCL22: change from baseline in CCL22 expression in lesions treated with crisaborole ointment 2% or vehicle at day 15</Description><Timeframe>Baseline, day 15</Timeframe></Measure><Measure><Description>Atopic dermatitis skin biomarker: K16: change from baseline in K16 expression in lesions treated with crisaborole ointment 2% or vehicle at day 15</Description><Timeframe>Baseline, day 15</Timeframe></Measure><Measure><Description>Atopic dermatitis skin biomarker: elafin/P13: change from baseline in elafin/P13 expression in lesions treated with crisaborole ointment 2% or vehicle at day 15</Description><Timeframe>Baseline, day 15</Timeframe></Measure><Measure><Description>Atopic dermatitis skin biomarker: IL-13: change from baseline in IL-13 expression in lesions treated with crisaborole ointment 2% or vehicle at day 15</Description><Timeframe>Baseline, day 15</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Atopic dermatitis biomarker expression: biomarker expression in lesional skin treated with crisaborole ointment 2% or vehicle at day 15 and levels in non lesional skin at baseline</Description><Timeframe>Baseline, day 15</Timeframe></Measure><Measure><Description>Atopic dermatitis gene expression: gene expression in lesional skin treated with crisaborole ointment 2% or vehicle at day 15 and levels in non lesional skin at baseline</Description><Timeframe>Baseline, day 15</Timeframe></Measure><Measure><Description>Investigator Static Global Assessment (ISGA): change from baseline in lesion severity as measured by ISGA at each visit up to day 15</Description><Timeframe>Baseline, day 8 and 15</Timeframe></Measure><Measure><Description>Other skin biomarkers of atopic dermatitis: change from baseline in expression of other skin biomarkers in lesions treated with crisaborole ointment 2% or vehicle at day 15</Description><Timeframe>Baseline, day 15</Timeframe></Measure><Measure><Description>Pruritus Numerical Rating Scale (NRS): change from baseline in lesion severity as measured by Pruritus NRS at each visit up to day 15</Description><Timeframe>Baseline, days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15</Timeframe></Measure><Measure><Description>Total Signs Score (TSS): change from baseline in lesion severity as measured by TSS at each visit up to day 15</Description><Timeframe>Baseline, day 8 and 15</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study was being conducted to characterize the mechanism of action of &lt;ulink linkType="Drug" linkID="55424"&gt;crisaborole&lt;/ulink&gt; ointment      2%, by evaluation of efficacy and changes in key skin biomarkers in atopic dermatitis (AD)      lesions treated with crisaborole ointment 2% over vehicle, in subjects with mild to moderate      AD.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Two identified AD skin lesions for each subject would be treated for the first 15 days, one with crisaborole ointment 2% and one with vehicle, in a blinded manner, and biopsies for biomarker analysis would be performed on the lesions. Following completion of the blinded treatment period, subjects would start the 28 day open-label period during which all AD affected skin lesions would be treated with crisaborole ointment 2% bid.&lt;/para&gt;&lt;para&gt;Subjects would be treated with Crisaborole ointment 2% bid or placebo for 15 days (double-blind); additional 28 days (open-label).&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Innovaderm Research Incorporated</Name><Address1>Montreal</Address1><Address2>Quebec</Address2><Address3>H2K 4L5</Address3><CountrySubDivision>Quebec</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Atopic Dermatitis</Disease><PatientSegments><PatientSegment><PatientSegment id="8564">Patients with Mild to Moderate Atopic Dermatitis</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03233529</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Atopic Dermatitis" id="45817"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Atopic Dermatitis" id="45818">Assessment of elafin/PI3 (peptidase inhibitor 3) levels</SubEndpoint><SubEndpoint disease="Atopic Dermatitis" id="45821">Assessment of S100 proteins</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Atopic Dermatitis" id="45822"><Endpoint>Assessment of Clinical Symptoms</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Atopic Dermatitis" id="45832"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Atopic Dermatitis" id="45833">Assessment of interleukins</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Atopic Dermatitis" id="45845"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Atopic Dermatitis" id="45817"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Atopic Dermatitis" id="45819"><Endpoint>Assessment of Clinical Response</Endpoint><SubEndpoints><SubEndpoint disease="Atopic Dermatitis" id="45825">Assessment of pruritus</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Atopic Dermatitis" id="45822"><Endpoint>Assessment of Clinical Symptoms</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Atopic Dermatitis" id="45845"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Atopic Dermatitis" id="45853"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Atopic Dermatitis" id="45854">Assessment of gene expression</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Atopic Dermatitis" id="46098"><Endpoint>Physician Global Assessment of Disease Activity</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Atopic Dermatitis" id="33532"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Atopic Dermatitis" id="33540"><Criterion>Subjects by disease severity</Criterion></Inclusion><Inclusion disease="Atopic Dermatitis" id="34474"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Atopic Dermatitis" id="33599">Subjects with protocol specified Investigator Global Assessment (IGA) scores</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Atopic Dermatitis" id="24254"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Atopic Dermatitis" id="24810">Subjects with unstable medical condition</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atopic Dermatitis" id="24806"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Atopic Dermatitis" id="24807">Hypersensitivity/contraindications to study medication/device</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atopic Dermatitis" id="24822"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Atopic Dermatitis" id="24827">Subjects co-morbid with premalignant/malignant condition</SubCriterion><SubCriterion disease="Atopic Dermatitis" id="24828">Subjects co-morbid with skin infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atopic Dermatitis" id="24830"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Atopic Dermatitis" id="26022"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Atopic Dermatitis" id="24836">Subjects with history/scheduled to receive steroids</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-05-04T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2018-04-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>9.03 Months</EnrollmentPeriod><EnrollmentRate>4.43 Patients/Month</EnrollmentRate><DateFirstReceived>2017-07-12T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-08-07T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-08-23T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-04-18T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-06-23T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial>